Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025
Edgewise Therapeutics, a leading muscle disease biopharmaceutical company, will be presenting at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. The presentation will be led by Kevin Koch, Ph.D., President and CEO, and is scheduled for 1:30 pm PT (4:30 pm ET). Key updates will cover the company's cardiovascular and muscular dystrophy programs and outline 2025 milestones. The presentation will be webcast live, and a replay will be available for a time on the Edgewise Events & Presentations page. Attendees are advised to connect several minutes early to ensure a timely connection.
Edgewise Therapeutics, un'azienda biopharmaceutica leader nelle malattie muscolari, parteciperà al 43° Annual J.P. Morgan Healthcare Conference il 13 gennaio 2025. La presentazione sarà guidata da Kevin Koch, Ph.D., Presidente e CEO ed è programmata per le 13:30 PT (16:30 ET). Gli aggiornamenti chiave riguarderanno i programmi cardiovascolari e distrofici muscolari dell'azienda e presenteranno i risultati attesi per il 2025. La presentazione sarà trasmessa in diretta streaming, e sarà disponibile una registrazione per un certo periodo sulla pagina Eventi e Presentazioni di Edgewise. Si consiglia ai partecipanti di collegarsi con diversi minuti di anticipo per garantire una connessione tempestiva.
Edgewise Therapeutics, una empresa biofarmacéutica líder en enfermedades musculares, presentará en la 43ª Conferencia Anual de Salud de J.P. Morgan el 13 de enero de 2025. La presentación será dirigida por Kevin Koch, Ph.D., Presidente y CEO, y está programada para 1:30 p. m. PT (4:30 p. m. ET). Las actualizaciones clave cubrirán los programas cardiovasculares y de distrofia muscular de la empresa y describirán los hitos de 2025. La presentación se transmitirá en vivo y se podrá acceder a una repetición durante un tiempo en la página de Eventos y Presentaciones de Edgewise. Se aconseja a los asistentes conectarse con varios minutos de antelación para asegurar una conexión oportuna.
엣지와이즈 테라퓨틱스, 주도적인 근육질환 생명공학 회사가 제43회 JP모건 헬스케어 컨퍼런스에서 2025년 1월 13일에 발표를 진행합니다. 발표는 케빈 코흐, Ph.D., 사장 겸 CEO가 이끌며, 오후 1:30 PT (오후 4:30 ET)로 예정되어 있습니다. 주요 업데이트는 회사의 심혈관 및 근이영양증 프로그램을 다루고 2025년의 이정표를 개요합니다. 발표는 실시간으로 웹캐스트되며, 엣지와이즈의 이벤트 및 발표 페이지에서 일정 기간 동안 재생이 가능합니다. 참석자들은 제시간에 연결할 수 있도록 몇 분 일찍 접속하는 것이 좋습니다.
Edgewise Therapeutics, une entreprise biopharmaceutique leader dans les maladies musculaires, présentera à la 43ème Conférence Annuelle J.P. Morgan Healthcare le 13 janvier 2025. La présentation sera dirigée par Kevin Koch, Ph.D., Président et CEO, et est prévue pour 13h30 PT (16h30 ET). Les mises à jour clés couvriront les programmes cardiovasculaires et de dystrophie musculaire de l'entreprise et décriront les étapes de 2025. La présentation sera diffusée en direct, et une rediffusion sera disponible pendant un certain temps sur la page Événements et Présentations d'Edgewise. Il est conseillé aux participants de se connecter plusieurs minutes à l'avance pour garantir une connexion rapide.
Edgewise Therapeutics, ein führendes biopharmazeutisches Unternehmen für Muskelerkrankungen, wird am 13. Januar 2025 auf der 43. jährlichen J.P. Morgan Healthcare Conference präsentieren. Die Präsentation wird von Kevin Koch, Ph.D., Präsident und CEO, geleitet und ist für 13:30 Uhr PT (16:30 Uhr ET) angesetzt. Wichtige Aktualisierungen werden die kardiovaskulären und muskeldystrophieprogrammen des Unternehmens abdecken und Meilensteine für 2025 skizzieren. Die Präsentation wird live im Web übertragen, und eine Wiederholung wird für einige Zeit auf der Seite Veranstaltungen & Präsentationen von Edgewise verfügbar sein. Den Teilnehmern wird geraten, sich einige Minuten früher zu verbinden, um eine rechtzeitige Verbindung sicherzustellen.
- None.
- None.
The presentation will be webcast live; a link for the webcast can be found on the Edgewise Events & Presentations page and will be accessible for replay, for a limited time, following the conference. It is recommended that users connect to the live webcast several minutes prior to the start to ensure a timely connection.
About Edgewise Therapeutics
Edgewise Therapeutics is a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s deep expertise in muscle physiology is driving a new generation of novel therapeutics. Sevasemten is an orally administered first-in-class fast skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, currently in Phase 2 clinical development. The entire team at Edgewise is dedicated to our mission: changing the lives of patients and families affected by serious muscle diseases. To learn more, go to: www.edgewisetx.com or follow us on LinkedIn, X , Facebook and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250107119700/en/
Edgewise Contacts
Investors:
Behrad Derakhshan, Ph.D., Chief Business Officer
ir@edgewisetx.com
Media:
Maureen Franco, VP Corporate Communications
media@edgewisetx.com
Source: Edgewise Therapeutics
FAQ
When will Edgewise Therapeutics present at the J.P. Morgan Healthcare Conference?
What will Edgewise Therapeutics discuss at the J.P. Morgan Healthcare Conference?
Who will present for Edgewise Therapeutics at the J.P. Morgan Healthcare Conference?
How can I watch the Edgewise Therapeutics presentation at the J.P. Morgan Healthcare Conference?
What time does the Edgewise Therapeutics webcast start?
